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S U M M A R Y
The burden of Schistosoma haematobium-associated bladder cancer is very high in Africa; nevertheless
the disease can pose considerable diagnostic challenges in low prevalence countries. We present the case
of a 40-year-old HIV co-infected woman, originally from Mozambique, who had persisting haematuria
for more than a year. Investigations revealed invasive S. haematobium-associated squamous cell bladder
cancer. If her origin had been taken into account, the diagnosis might have been made earlier. Awareness
of the disease prevalence among HIV co-infected patients from endemic areas and timely screening of
such patients is important for the early diagnosis of schistosomiasis and related complications, such as S.
haematobium-associated squamous cell bladder cancer.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Schistosomiasis, or bilharzia, is an acute and chronic disease
caused by the trematodes of the genus Schistosoma. Schistoso-
miasis is one of the World Health Organization’s (WHO)
17 neglected tropical diseases. Furthermore, the WHO has
estimated that 249 million people required preventive treat-
ment for schistosomiasis in 2012 and that at least 90% of these
people live in Africa.1
There are ﬁve main species of Schistosoma: S. mansoni, S.
haematobium, S. japonicum, S. intercalatum, and S. mekongi. These
species vary in geographic distribution and importance.1 S.
haematobium is responsible for the urogenital manifestations of
the disease and causes more than half of worldwide Schistosoma
infections.2 The adult S. haematobium inhabit the venules
surrounding organs of the pelvis where they lay between
20 and 200 eggs daily. The secreted eggs cause inﬂammatory
and granulomatous reactions in the vesical and urethal walls,
resulting in symptoms such as pelvic pain, post-coital bleeding,
and haematuria.1,2 Squamous cell bladder carcinoma, together
with chronic renal failure, is considered a long-term consequence
of chronic urogenital schistosomiasis; these serious complications* Corresponding author. Tel.: +45 20686156.
E-mail address: lhmarbjerg@gmail.com (L.H. Marbjerg).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).can be prevented by early anti-schistosomal treatment with
praziquantel.3
The control of schistosomiasis is based on large-scale treatment
of persons at risk, together with improved sanitation, hygiene
education, snail control, and access to safe water. Unfortunately,
only 14.4% of people requiring treatment aimed at reducing the
disease and morbidities were reached in 2012.1
The case patient presented below originates from Mozambique,
where the overall prevalence of S. haematobium is 47% and the
prevalence of HIV infection in adults aged 15–49 years was 10.8%
in 2013 according to the WHO.
2. Case report
A 40-year-old woman was evaluated for haematuria. The
patient originally came from Mozambique and had immigrated to
Denmark in 2002. She was diagnosed with an HIV infection in
2001 in Mozambique. At that time her CD4 cell count was
126 cells/ml and antiretroviral treatment was initiated. The ﬁrst
laboratory results in Denmark showed a CD4 cell count of
380 cells/ml and HIV RNA of <40 copies/ml. The patient had no
AIDS-deﬁning diagnosis and was a non-smoker. She was newly
transferred to our outpatient clinic for HIV care.
At a routine consultation for HIV, the patient complained of
small amounts of bleeding after voiding for about a year. She also
had intermittent dysuria. Her general practitioner had investigatedciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. (A) CT showing a tumour on the posterior wall of the bladder. (B) Histopathological examination showing muscle-invasive squamous cell carcinoma and
Schistosoma eggs.
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without growth. Her haemoglobin was 7.2 mmol/l (normal range
7.3–9.5 mmol/l), leukocyte count was 3.4  109/l (normal range
3.5–8.8  109/l) without eosinophilia, and C-reactive protein was
6.0 mg/l (normal range <6 mg/l). Kidney and liver function were
normal. A routine gynaecological examination, ultrasound, and
cervical smear 5 months earlier had found a normal cervix and
uterus. In addition, cervical cytology was normal. She was referred
to the Department of Urology for further examination of persisting
haematuria.
Computed tomography (CT)-urography revealed thickening of
the posterior wall of the bladder (Figure 1A). Subsequently a
transurethral resection of the bladder (TURB) showed a solid
broad-based tumour on the posterior wall of the bladder spreading
to the left. Furthermore, there were papillary lesions bilaterally.
The histopathological result was poorly differentiated squamous
cell carcinoma. In several of the tissue samples there were partially
calciﬁed Schistosoma eggs. In some places the carcinoma was
muscle-invasive (Figure 1B). On staging, the tumour was evaluated
to be T2b.
Following the TURB, an integrated CT and positron emission
tomography (PET) was done. This showed pathological activity in
several places in the wall of the bladder and in a few of the iliac
lymph nodes. A biopsy of one of the iliac lymph nodes was then
performed. Fortunately, histopathological examination of the
lymph node did not show signs of malignancy. The patient then
underwent robotic-assisted radical cystectomy and hysterectomy.
An orthotopic neobladder was constructed and 13 lymph nodes
were removed.
The ﬁnal histopathological examination revealed that none of
the removed lymph nodes showed signs of malignancy. Neither the
uterus nor the cervix was affected. The ﬁnal stage was recorded as
pT2aN0M0. Because the disease was not disseminated, the patient
did not undergo chemotherapy. The patient was clinically well
postoperatively and she had no major complaints with respect to
her orthotopic neobladder. Her CD4 count has since been >500
cells/ml and HIV RNA undetectable.
3. Discussion
Epidemiological studies of HIV and S. haematobium in Africa
show a substantial overlap between regions where S. haemato-
bium is endemic and regions with a high prevalence of HIV
infection.2 A study from Zimbabwe found that women with S.
haematobium ova in the genital tract had a three-fold increasedrisk of having HIV, and in Tanzania women with S. haematobium
infection were found to have a four-fold risk of having HIV.2
Schistosomiasis usually precedes infection with HIV and it
appears likely that urogenital schistosomiasis increases the risk
of HIV acquisition.2 Women with S. haematobium may have
lesions in the genital tract, referred to as female genital
schistosomiasis (FGS),4 which may facilitate HIV entry.2 More-
over it has been hypothesized that sustained systemic chronic
stimulation of the immune system caused by S. haematobium
increases susceptibility to HIV. Monocytes and T-cells expressing
the CD4 receptor and the chemokine receptor CCR5 can be
infected with HIV.4 A study from South Africa showed that
women with FGS had a higher frequency of CD4+ T-cells
expressing CCR5 in blood samples than FGS-negative women.
It was also found that this proportion decreased signiﬁcantly after
treatment with praziquantel. In cervical cytobrush-derived cells,
a higher CCR5 expression on CD4+ cells in women with FGS
compared to women without FGS was found.4
Furthermore, evidence suggests that S. haematobium may
accelerate HIV disease progression, by raising plasma HIV RNA.2
Does HIV infection accelerate the long-term complications of
chronic schistosomiasis? This needs to be elucidated.
The 5-year disease-free survival rate after radical cystectomy
due to squamous cell carcinoma is 57.7%. Factors with signiﬁcant
and independent inﬂuence on survival are tumour pathological
stage, histological grade, and lymph node status.5 Early diagnosis is
of pivotal importance for the disease-free survival rate.
In low-prevalence settings, routine schistosomiasis screening
and treatment of the population at risk appear to comprise an
important public health tool. In an HIV clinic in Glasgow, all
patients of African origin were screened for schistosomiasis using
antibody tests to determine the prevalence. In total, 17% of all HIV
cases were positive and offered treatment.3 A positive antibody
test among patients at known risk would lead to the early
diagnosis and treatment of schistosomiasis in low-prevalence
countries. However, due to low sensitivity and speciﬁcity of the
antibody test, the diagnostic work-up should be combined with
direct tests.
This patient was fortunate that the disease had not metasta-
sized and no lymph nodes were involved at the time of diagnosis. If
the patient’s symptoms had been considered in relation to her
origin, the diagnosis might have been made earlier. It is important
to remember that persistent haematuria is a warning sign and
needs to be taken seriously.
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